CEO Tells San Francisco Forum That It Treats the Largest Glaucoma Patient Segment
SAN FRANCISCO, Jan. 12, 2015 /PRNewswire/ — InnFocus, Inc. reports the InnFocus MicroShunt® has now been used in more than 100 glaucoma surgeries worldwide, in the current configuration and surgical technique, with patients followed for up to three years. Results outside the United States show patients achieve a mean Intra Ocular Pressure (IOP) below 14 mmHg after implantation of the InnFocus MicroShunt® which studies show is key for stopping the progression of vision loss in glaucoma sufferers. Patients experience over 80% reduction in their eye drop medication use–and over 70% are off medications completely at 3 years.
Logo – http://photos.prnewswire.com/prnh/20150112/168465LOGO
"Studies outside the US indicate we provide a safe and effective treatment for early to late stage open angle glaucoma patients, that is intuitively easy for the surgeon to perform," said Russ Trenary, InnFocus CEO. "We address the largest glaucoma patient segment in a large and growing market."
Trenary made the comments at the 8th OneMedForum in San Francisco, which is a conference dedicated to strategic insight on the future of healthcare, life sciences and medicine and attracted industry leaders and investors. The conference runs through Wednesday (January 14th).
The InnFocus MicroShunt® glaucoma drainage implant, made from the Company's revolutionary SIBS material which has a 13-year proven history in drug eluting coronary stents and 7 years in ophthalmology, is ultra-stable, and will not degrade.
Glaucoma affects over 78 million people worldwide. The disease is a serious health care problem that is not always easy to diagnose, and treatments heretofore have proven to have only temporary results.
The InnFocus MicroShunt® consists of a microtube about the twice the size of an eyelash. It is currently in Phase 1 Food and Drug Administration trials at 12 centers in the United States. Patients have also been treated in France, Japan, Netherlands, Spain, Switzerland, and the Dominican Republic.
The InnFocus MicroShunt® has been implanted alone or in combination with cataract surgery in clinical trials outside the United States. It was developed in collaboration with the University of Miami's Bascom Palmer Eye Institute. It provides a quick and simple method of shunting aqueous humor from the anterior chamber to a diffuse bleb without the use of a scleral flap.
It uses a patented micro-shunt made from the innovative SIBS Material to control flow. The mechanism of action for the InnFocus MicroShunt® of subconjunctival/Tenons drainage has been the accepted gold standard for decades.
CAUTION: INVESTIGATIONAL DEVICE. LIMITED TO INVESTIGATIONAL USE IN THE UNITED STATES.
WEBSITE: www.innfocusinc.com
MEDIA CONTACT:
ED COGHLAN
PHONE: 818-489-4774